Regeneron Pharmaceuticals has entered into a strategic partnership with Parabilis Medicines to develop innovative therapeutic candidates utilizing Parabilis’ Helicon™ peptide platform, focusing on Antibody-Helicon™ Conjugates (AHCs) aimed at “undruggable” targets. The agreement includes $125 million for Parabilis—a $50 million upfront payment and a $75 million equity commitment—along with potential milestone payments of up to $2.2 billion. This collaboration aims to combine Regeneron’s antibody technology with Helicon peptides to enhance targeted drug delivery and create a new therapeutic class.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas/2346076
